COVID-19 Community of Practice for Ontario Family Physicians

Jan 19, 2024

Dr. Alon Vaisman Dr. Tasha Stoltz Dr. Daniel Warshafsky



### **COVID-19 Updates and Managing Respiratory Illness in Kids**





### **COVID-19 Updates and Managing Respiratory Illness in Kids**

Moderator:

 Dr. Ali Damji, Division Head, Primary Care, Trillium Health Partners and Family Physician, Credit Valley Family Health Team, Mississauga, ON

Panelists:

- Dr. Alon Vaisman, Toronto, ON
- Dr. Tasha Stoltz, Kitchener, ON
- Dr. Daniel Warshafsky, Toronto, ON

Host:

• Dr. Mekalai Kumanan, Cambridge, ON

The COVID-19 Community of Practice for Ontario Family Physicians is a one-credit-per-hour Group Learning program that has been certified for up to a total of 32 credits.

### Land Acknowledgement

We acknowledge that the lands on which we are hosting this meeting include the traditional territories of many nations.

The OCFP and DFCM recognizes that the many injustices experienced by the Indigenous Peoples of what we now call Canada continue to affect their health and well-being. The OCFP and DFCM respects that Indigenous people have rich cultural and traditional practices that have been known to improve health outcomes.

I invite all of us to reflect on the territories you are calling in from as we commit ourselves to gaining knowledge; forging a new, culturally safe relationship; and contributing to reconciliation.

"I'm so grateful that I can speak even a little bit of my language, which I'm not fluent enough [in] here, because in this business, Native actors used to speak their lines in English and then the sound mixers would <u>run them backwards</u> to accomplish Native languages on camera," said Gladstone. "This is an historic [award]. It doesn't belong to just me."

### Lily Gladstone is first Indigenous woman to win best actress in a drama at Golden Globes

'I'm so grateful that I can speak even a little bit of my language,' said Gladstone

Jenna Benchetrit · CBC News · Posted: Jan 08, 2024 2:59 PM EST | Last Updated: January 8



Lily Gladstone accepts the Golden Globe award for best female actor in motion picture (drama) for playing Osage woman Molly Kyle in Martin Scorsese's Killers of the Flower Moon. She is the first Indigenous actress to win the award. (Sonja Flemming/CBS/The Associated Press)

### Changing the way we work

### A community of practice for family physicians during COVID-19

At the conclusion of this <u>series</u> participants will be able to:

- Identify the current best practices for delivery of primary care within the context of COVID-19 and how to incorporate into practice.
- Describe point-of-care resources and tools available to guide decision making and plan of care.
- Connect with a community of family physicians to identify practical solutions for their primary care practice under current conditions.

### **Disclosure of Financial Support**

This CPD program has received in-kind support from the Ontario College of Family Physicians and the Department of Family and Community Medicine, University of Toronto in the form of logistical and promotional support.

### **Potential for conflict(s) of interest:** N/A

### **Mitigating Potential Bias**

- The Scientific Planning Committee has full control over the choice of topics/speakers.
- Content has been developed according to the standards and expectations of the Mainpro+ certification program.
- The program content was reviewed by a three-member national/scientific planning committee.

*Planning Committee*: Dr. Tara Kiran (DFCM), Dr. Mekalai Kumanan (OCFP), Dr. Ali Damji (DFCM), Dr. Eleanor Colledge (DFCM) Dr. Harry O'Halloran, Mina Viscardi-Johnson (OCFP), Julia Galbraith (OCFP), Pavethra Yogeswaran (OCFP), Marisa Schwartz (DFCM), Erin Plenert (DFCM)

### Previous webinars & related resources:

https://www.dfcm.utoronto.ca/covid-19-community-practice/past-sessions



### Dr. Alon Vaisman – Panelist

Infectious Diseases and Infection Control Physician, University Health Network



### **Dr. Tasha Stoltz – Panelist** Pediatrician, Kitchener, ON



### Dr. Daniel Warshafsky – Panelist

Associate Chief Medical Officer of Health at the Office of the Chief Medical Officer of Health



### **Dr. Mekalai Kumanan – Host** Twitter: @MKumananMD

President, Ontario College of Family Physicians Family Physician, Two Rivers Family Health Team Chief of Family Medicine, Cambridge, ON

### **Speaker Disclosure**

- Faculty Name: **Dr. Alon Vaisman**
- Relationships with financial sponsors:
  - Grants/Research Support: N/A
  - Speakers Bureau/Honoraria: Ontario College of Family Physicians
  - Membership on advisory boards: N/A
  - Others: N/A
- Faculty Name: **Dr. Tasha Stoltz**
- Relationships with financial sponsors: McMaster University (Regional Education Lead Undergraduate Pediatrics)
  - Grants/Research Support: N/A
  - Speakers Bureau/Honoraria: Ontario College of Family Physicians
  - Membership on advisory boards: N/A
  - Others: N/A

### **Speaker Disclosure**

- Faculty Name: Dr. Daniel Warshafsky
- Relationships with financial sponsors:
  - Grants/Research Support: N/A
  - Speakers Bureau/Honoraria: N/A
  - Others: N/A
- Faculty Name: Dr. Mekalai Kumanan
- Relationships with financial sponsors:
  - Grants/Research Support: N/A
  - Speakers Bureau/Honoraria: Ontario College of Family Physicians
  - Others: Chief of Family Medicine, Cambridge Memorial Hospital
- Faculty Name: **Dr. Ali Damji**
- Relationships with financial sponsors:
  - Grants/Research Support: N/A
  - Speakers Bureau/Honoraria: Ontario College of Family Physicians
  - Others: N/A

### **How to Participate**


• All questions should be asked using the Q&A function at the bottom of your screen.



• Press the thumbs up button to upvote another guests questions. Upvote a question if you want to ask a similar question or want to see a guest's question go to the top and catch the panels attention.

😋 Q&A			
	All questions (1)	My questions	
Lee 01:54 PM			
Will there be a foll	low-up session?		
ıЪ			Comment

• Please use the chat box for networking purposes only.





### Dr. Alon Vaisman – Panelist

Infectious Diseases and Infection Control Physician, University Health Network



### **Dr. Tasha Stoltz – Panelist** Pediatrician, Kitchener, ON


# The Current State of COVID

### Alon Vaisman MD MAS FRCPC

Hospital Epidemiologist, Infection Prevention and Control Infectious Disease Specialist University Health Network










## OBJECTIVES


 The current state of COVID variants, morbidity, treatments, and vaccines 2 No words, just pictures!














https://www.covid19immunitytaskforce.ca/seroprevalence-in-canada/







Week start date




VACCINES


NACI recommends that:

- Starting in the spring of 2024, the following individuals who are at increased risk of severe illness from COVID-19 may receive an additional dose of XBB.1.5 COVID-19 vaccine:
  - Adults 65 years of age and older
  - Adult residents of long-term care homes and other congregate living settings for seniors
  - Individuals 6 months of age and older who are moderately to severely immunocompromised (due to underlying conditions or treatment)

https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine/summary-updates-june-27-2023.html







*Pediatrics* (2023) 151 (4): e2022059513.





## TREATMENT

	initess severity		
	Mild	Moderate	Severe
Severity Criteria	no new need for supplemental oxygen	receiving low-flow supplemental oxygen	oxygen via high-flow nasal cannula, non-invasive positive pressure ventilation, or invasive mechanical ventilation
<b>Preferred Antiviral</b>	nirmatrelvir/ritonavir x 5 days	remdesivir x 5 days	none
	OR		
Alternative Antiviral	remdesivir x 3 days		
Immunomodulator	none	dexamethasone	dexamethasone
		+/- IL-6 <u>OR</u> JAK inhibitor	+/- IL-6 <u>OR</u> JAK inhibitor

### **Illness Severity**








### CONCLUSIONS

 Omicron is highly transmissible, infection is highly probable

- 2 New variants are inevitable
- Vaccines are less effective in the omicron era



### Resources to support your practice

Writing Sick Notes

To help educate employers on changing their policies, the OCFP has created this resource for use in your EMRs and clinic workflows for sick notes.

### Did you know that most employers in Ontario have eliminated the requirement for sick notes for short-term illnesses?

While the <u>Employment Standards Act</u> permits employers to ask employees for medical notes when taking sick leave, it is not a requirement of the Act for employers to ask their employees to provide a medical note for absences lasting five days or less. In fact, other provinces have amended their legislation to prohibit employers from doing so.

#### HERE'S WHY YOUR ORGANIZATION SHOULD RECONSIDER REQUIRING SICK NOTES:



Sick notes impact employee and economic productivity. <u>Many employees</u> would rather go to work ill than spend the time and money getting a sick note, leading to illness spreading in the workplace.

Sick notes strain healthcare resources and take time from patients who need urgent care. Patients should see a doctor only if they require medical care—most common illnesses can be <u>managed at home</u>.



Sick employees should stay home. Travelling to a doctor's appointment or emergency department for a sick note hinders recovery and needlessly exposes vulnerable patients and healthcare providers to illness.

Doctors rely on patient's self-reporting of their illness and may not be able to verify it from a medical standpoint.



Many patients are **charged a fee** for sick notes because OHIP does not compensate doctors for providing this non-medical service.

Some patients can't access a doctor during their illness. There is a <u>shortage of</u> <u>family doctors in Ontario</u>. As a result, some patients are unable to get a timely appointment. Over 2 million Ontarians don't have a family doctor at all, and must seek care (and sick notes) through walk-in clinics and emergency departments.






### Resources to support your practice

# Changes to the CPSO *Continuity of Care: Advice to the Profession*

Ontario College of Family Physicians

These updates provide greater clarity around administrative responsibilities for specialists and emphasize clear communication between consultants and family physicians.

## What you need to know:



https://www.ontariofamilyphysicians.ca/wp-content/uploads/2023/12/ocfpcontinuity-of-care-letter-templates.docx

02

**Ordering Tests** 

## Coughing, Wheezing and Sneezing: Respiratory illnesses in children

Tasha Stoltz, MD FRCPC Consultant Pediatrician Grand River Hospital, Kitchener ON




- Review pathophysiology of common pediatric respiratory illnesses
  - URTI
  - Croup
  - Bronchiolitis
  - Pneumonia
  - Asthma
- Discuss approach to diagnosis and evidencebased treatment strategies



## **Upper respiratory tract infections**

- Sneezing, stuffy/runny nose, headache, sore throat, cough may be present
- Always viral in cause
- Diagnosis is clinical
  - NPS not necessary
- Treatment is supportive
  - No role for PO/inhaled/intranasal steroids, inhalers or antibiotics




## Croup

- Acute-onset upper airway obstruction secondary to viral infection
- 6 months-3 years of age
- Barky cough +/- stridor
- Rule out: bacterial tracheitis, epiglottitis, retropharyngeal abscess, anaphylaxis, foreign body aspiration
  - Toxic-appearing, drooling, dysphagia is NOT croup



## Croup


- Diagnosis is clinical
  - CXR/lateral neck XR, swabs are NOT necessary for diagnosis
- Treatment:
  - PO dexamethasone 0.6 mg/kg x 1
  - NO antibiotics
- To ED if:
  - Stridor or WOB at rest, biphasic stridor
  - Hypoxia or cyanosis
  - Drooling or dysphagia
  - Lethargy or distress



## **Bronchiolitis**

- Viral LRTI in children <2 years
- Can be caused by any virus, including RSV
- Fever, cough and rhinorrhea, wheeze, crackles +/- respiratory distress
- Rule out: asthma, pneumonia, foreign body aspiration

Table 4	
Groups at higher risk for severe disease	
Infants born prematurely (<35 weeks' gestation)	
<3 months of age at presentation	
Hemodynamically significant cardiopulmonary diseas	e
Immunodeficiency	



References: Bronchiolitis: Recommendations for diagnosis, monitoring and management of children one to 24 months of age (Canadian Pediatric Society)


## **Bronchiolitis**

- Diagnosis is clinical
  - X-rays not necessary for diagnosis, usually non-specific only if severe or alternate diagnosis suspected
  - Labs not necessary
  - NPS not necessary
- Treatment:
  - Supportive hydration, nasal suctioning?
  - No evidence for use of Ventolin, steroids, antibiotics, antivirals
- To ED if any concerns about RR, WOB, O2 saturations, menta status, apneas, or hydration concerns
- Symptoms usually peak on day 5

References: Bronchiolitis: Recommendations for diagnosis, monitoring and management of children one to 24 months of age (Canadian Pediatric Society)

## **Bacterial Pneumonia**

- Fever, cough, appears 'sicker', +/- respiratory distress
- Focal crackles (not wheeze!) on examination
- Diagnosis:
  - CXR focal lobar consolidation or worse (parapneumonic effusion, empyema, abscess, etc)
  - Atypical pathogens can have bilateral infiltrates
  - NPS, labs not indicated for outpatients



## **Bacterial Pneumonia**

- Treatment:
  - Uncomplicated: Amoxicillin 90 mg/kg/day divided TID x 5 days
  - Atypicals treatment with macrolides is controversial
- Improvement usually within 48 hours of antibiotics
- Repeat CXR after illness is not necessary in children if clinical improvement
- To ED if any concerns about RR, WOB, O2 saturations, mental status, apneas, or hydration concerns

References: <u>Uncomplicated pneumonia in healthy Canadian children and youth (Canadian Pediatric Society)</u>

### **Asthma**

- Recurrent wheeze that is responsive to bronchodilator treatment
- Typically personal or family history of atopy

- Asthma guidelines:
  - Diagnosis and management of asthma in preschoolers
  - Diagnosis and management of asthma in preschoolers, children and adults
  - Managing an acute asthma exacerbation in children
  - ICS for asthma therapy in children
  - The management of very mild and mild asthma in preschoolers, children and adolescents

# **Asthma – Controller Therapy**


- Trigger avoidance and manage comorbidities
- Common triggers: infection, physical activity, allergens, cold air, pollution, poor compliance
- Written asthma action plan
- Aerochambers!
- ICS use:
  - Ensure compliance
  - Need to use 3-4 weeks for any effect
  - Review side effects with parents

References: Managing an acute asthma exacerbation in children (	(Canadian Pediatric Society)
	· · · · · · · · · · · · · · · · · · ·

6 to 11 years: 50 to 100 mcg twice daily ≥12 years: 100 mcg twice daily     6 to 11 years: 200 twice daily       Budesonide (Pulmicort) φ Dry powder inhaler # -100 or 200 mcg/puff     ≥6 years: 100 to 200 mcg twice daily     ≥6 years: 400 mcg twice daily       Budesonide/LABA for 21 years:     ≥12 years: 100 to 200 mcg twice daily     ≥12 years: 400 mcg twice daily       Ciclesonide (Alvesco) φ§ MDI/spacer - 100 or 200 mcg/puff     ≥12 years: 100 to 200 mcg twice daily     ≥12 years: 400 mcg twice daily       Fluticasone propionate (Flovent) φ MDI/spacer - 50, 125, 250 mcg/puff     1 to 5 years: 50 mcg twice daily or 125 mcg once daily ±     1 to 5 years: 100 to 100 mcg twice daily or 125 mcg once daily ±       Fluticasone propionate/LABA for 24 years:     ≥12 years: 100 to 25 mcg twice daily ≥12 years: 125 mcg once or twice daily     1 to 5 years: 200 mcg twice ≥12 years: 250 mcg twice daily       Fluticasone propionate/LABA for 24 years:     ≥12 years: 100 to 25 mcg twice daily     1 to 11 years: 100 to 125 mcg twice	Medication (trade name) Inhaler device - Formulation	Low corticosteroids dose for age	Medium corticosteroids dose for a
Dry powder inhaler ‡ -100 or 200 mcg/puff     26 years: 100 to 200 mcg twice daily     26 years: 400 mcg twice daily       Budesonide/LABA for 312 years : Budesonide/Formuterol (Symbiort) Dry powder inhaler 1 - 100(6, 200/6 mcg/puff     212 years: 100 to 200 mcg twice daily     212 years: 400 mcg twice daily       Ciclesonide (Alvesco) φ\$ MDI/spacer - 100 or 200 mcg/puff     1 to 5 years: 100 mcg once daily     26 years: 400 mcg twice daily       Fluticasone propionate (Flovent) φ MDI/spacer - 50, 125, 250 mcg/puff     1 to 5 years: 50 mcg twice daily or 125 mcg once daily it     1 to 5 years: 200 mcg once daily       Fluticasone propionate/LABA for 34 years:     212 years: 100 to 250 mcg twice daily or 125 mcg once daily it     1 to 5 years: 200 mcg twice daily or 125 mcg once daily it       Fluticasone propionate/LABA for 34 years:     212 years: 100 to 25 mcg twice daily or 125 mcg once daily it     1 to 11 years: 200 mcg twice daily or 125 mcg once daily it       Fluticasone propionate/LABA for 34 years:     212 years: 100 to 25 mcg twice daily or 125 mcg once daily it     4 to 11 years: 100 to 125 mcg twice daily or 124 years: 250 mcg twice daily       Fluticasone Fuorate (Arnuity Ellipta) § Dry powder inhaler + 100 or 200 mcg/puff     212 years: 100 mcg once daily     4 to 11 years: 250 mcg twice daily or 124 years: 250 mcg twice daily       Fluticasone fuorate/LABA for 31 years     212 years: 100 mcg once daily     4 to 11 years: 250 mcg twice daily		6 to 11 years: 50 to 100 mcg twice daily	1 to 5 years: 100 mcg twice daily 6 to 11 years: 200 twice daily ≥12 years: 200 mcg twice daily
for 312 years:       ≥12 years: 100 to 200 mcg twice daily       ≥12 years: 400 mcg twice d         Dry powder Inhaler I - 100/6, 200/6 mcg/puff or 400/12       >1 to 5 years: 100 mcg once daily       ≥12 years: 400 mcg twice d         Ciclesonide (Alvesco) φ§       1 to 5 years: 100 mcg once daily       26 years: 400 mcg once daily       26 years: 400 mcg once daily         Fluticasone propionate (Flovent) φ       1 to 5 years: 50 mcg twice daily       1 to 5 years: 50 mcg twice daily       6 to 11 years: 50 to 100 mcg twice daily         Fluticasone propionate/LABA       or 125 mcg once daily 1       6 to 11 years: 50 to 100 mcg twice daily       1 to 1 years: 250 mcg twice daily         Fluticasone propionate/LABA       for 24 years:       212 years: 120 mcg once daily 1       4 to 11 years: 00 to 125 mcg twice daily         Pry powder inhaler I - 100/50 or 250/50 mcg/puff       212 years: 120 to 25 mcg twice daily       4 to 11 years: 100 to 125 mcg twice daily         Fluticasone propionate/LABA       212 years: 100 to 25 mcg twice daily       212 years: 250 mcg twice daily         Pry powder inhaler I - 100/50 or 250/50 mcg/puff       212 years: 100 mcg once daily       4 to 11 years: 00 to 125 mcg twice daily         Fluticasone fuorate/LABA       for 21 years:       100 r200 mcg/puff       212 years: 100 mcg once daily         Fluticasone fuorate/LABA       for 21 years:       212 years: 100 mcg once daily       212 years: 250 mcg twice daily		≥6 years: 100 to 200 mcg twice daily	≥6 years: 400 mcg twice daily
MDl/spacer - 100 or 200 mcg/puff     1 to 5 years: 100 mcg once daily 26 years: 100 to 200 mcg once daily 26 years: 100 to 200 mcg once daily 26 years: 100 to 200 mcg once daily 1 to 5 years: 200 mcg once daily 0 r125 mcg once daily 1 6 to 11 years: 200 mcg twice daily or 125 mcg once daily 1 6 to 11 years: 200 mcg twice daily or 125 mcg once daily 1 212 years: 100 to 25 mcg twice daily or 125 mcg once daily 1 212 years: 100 to 25 mcg twice daily 212 years: 200 mcg twice daily 212 years: 100 to 25 mcg twice daily 212 years: 200 mcg twice daily 212 years: 100 to 25 mcg twice daily 212 years: 200 mcg twice daily 212 years: 200 mcg twice daily 212 years: 100 to 25 mcg twice daily 212 years: 200 mcg tw	for ≥12 years : Budesonide/Formoterol (Symbicort)	≥12 years: 100 to 200 mcg twice daily	≥12 years: 400 mcg twice daily
MD1/spacer - 50, 125, 250 mcg/puff or Dry powder inhaler ∔ - 100 or 250 mcg/puff       1 to 5 years: 50 mcg twice daily or 125 mcg ponce daily # 6 to 11 years: 50 to 100 mcg twice daily or 125 mcg ponce daily # 122 years: 125 mcg twice daily       1 to 5 years: 100 to 125 mcg twice 6 to 11 years: 20 mcg twice daily or 125 mcg ponce daily # 122 years: 125 mcg twice daily       1 to 5 years: 100 to 125 mcg twice 6 to 11 years: 20 mcg twice daily         Fluticasone propionate/LABA for ≥4 years:       212 years: 125 mcg twice daily       4 to 11 years: 00 to 125 mcg twice daily         Pluticasone propionate/LABA for ≥4 years:       212 years: 100 to 25 mcg twice daily       4 to 11 years: 100 to 125 mcg twice daily         Pluticasone Fuorate/LABA for 21 years:       212 years: 100 mcg once daily       212 years: 250 mcg twice daily         Pluticasone fuorate/LABA for 21 years:       212 years: 100 mcg once daily       212 years: 100 mcg once daily         Fluticasone fuorate/LABA for 21 years:       212 years: 100 mcg once daily       212 years: 100 mcg once daily			1 to 5 years: 200 mcg once daily ≥6 years: 400 mcg once daily
for ski years:     for ski years:     212 years: 100 to 25 mcg twice daily     4 to 11 years: 100 to 125 mcg twice daily       MU/spacer - 125/25, 520/25 mcg/puff ar     212 years: 100 to 25 mcg twice daily     212 years: 250 mcg twice daily       Fluticasone Fuorate (Arnuity Ellipta) §     212 years: 100 mcg once daily     212 years: 100 mcg once daily       Fluticasone fuorate/LABA for s12 years:     212 years: 100 mcg once daily     212 years: 100 mcg once daily	MDI/spacer - 50, 125, 250 mcg/puff or	or 125 mcg once daily ¤ 6 to 11 years: 50 to 100 mcg twice daily or 125 mcg once daily ¤	1 to 5 years: 100 to 125 mcg twice dai 6 to 11 years: 200 mcg twice daily ≥12 years: 250 mcg twice daily
Dry power inhaler 100 or 200 mcg/puff ≥12 years: 100 mcg once daily  Fluticasone fuorate/LABA for 121 years: 212 years: 100 mcg once daily Fluticasone fuorate/laterol (Breo Ellipta)§	for ≥4 years: Fluticasone propionate/salmeterol (Advair) MDI/spacer – 125/25, 250/25 mcg/puff or	≥12 years: 100 to 25 mcg twice daily	4 to 11 years: 100 to 125 mcg twice da ≥12 years: 250 mcg twice daily
for ≿12 years: ≥12 years: 100 mcg once daily Fluticasone furoate/vilanterol(Breo Ellipta)§		≥12 years: 100 mcg once daily	
	for ≥12 years: Fluticasone furoate/vilanterol (Breo Ellipta)§	≥12 years: 100 mcg once daily	

## **Asthma - Exacerbation**

- Diagnosis is clinical no CXR/other investigations required
- Use rescue puffer q4h routinely during an exacerbation
- Oral corticosteroids
  - PO dexamethasone 0.3-0.6 mg/kg x 1-2 days
  - PO prednisolone 1 mg/kg x 3-5 days
- NO evidence for:
  - Increasing ICS dose during illness
  - Short-term, intermittent use of ICS



References: Managing an acute asthma exacerbation in children (Canadian Pediatric Society)

# **Post-Viral Cough**

- Manage expectations
- Cough can last 4-6 weeks post-viral infection
- No investigations required unless associated with other features or >6 weeks in duration in otherwise healthy children
- Avoid exacerbating factors (eg smoke, allergens)
- Avoid OTC cough suppressants, especially in kids <6 years</li>
- Honey can be used >1 year of age
- Humidifiers


### Vaccines

### • COVID-19:

- Recommended for all children ≥5 years
- Recommended for all children 6 months to 4 years at high risk for severe illness, and other children MAY be vaccinated

### • RSV:

- Synagis (palivizumab) vaccine currently available
- Stay tuned for some upcoming changes...



References: COVID-19 vaccine for children and adolescents (Canadian Pediatric Society)



- The diagnosis is in the history and exam
- If you hear a wheeze, CXR usually not required
- If you hear crackles, CXR to diagnose bacterial pneumonia before antibiotics





	Presentation	Management
Viral URTI	Sneezy, snuffy nose	Supportive treatment
Croup	Barky cough, inspiratory stridor	Dexamethasone
Bronchiolitis	Fever, cough, wheeze, crackles	Supportive treatment
Bacterial pneumonia	High-grade fevers, cough, crackles	Amoxicillin 90 mg/kg/day div TID
Asthma	Recurrent wheeze	Ventolin +/- ICS (depending on severity) with PO steroids if acute exacerbation
Post-viral cough	Persistent cough x 4-6 weeks	Supportive treatment +/- honey Humidifiers



## Are you a healthcare professional with a question about COVID-19 therapeutics?

Staffed by a registered pharmacist, OPA's COVID-19 Therapeutic Support Line provides Ontario vaccinators and prescribers with a dedicated resource to assist with timely, evidence-based clinical decision-making support.



**1-888-519-6069** 10 am – 8 pm EST, 7 days per week

#### **Contact Us Today!**



opatoday.com/ covid19support

https://www.opatoday.com/covid19support/

To help Toronto's school-aged children and youth catch-up on routine vaccines, TPH will hold a number of community vaccine clinics beginning **Friday January 19th, 2024**. The clinics will offer vaccines for the <u>nine</u> <u>Immunization of School Pupils Act (ISPA) diseases</u>, as well as the human papillomavirus and hepatitis B vaccines.

#### Beginning January 25th, clinics will also offer:

- COVID-19 vaccines for children under five years of age
- Novavax XBB COVID-19 vaccine, a protein subunit vaccine for individuals 12 years of age and over who have been unable (i.e., due to allergy) or unwilling to receive an mRNA COVID-19 vaccine.

For the above mentioned COVID-19 vaccines, advise eligible patients that they may get these vaccines at a TPH community vaccine clinic. Appointments are required and can be <u>booked online</u> beginning **January 23rd**. A health card is not required.

• Remind parents to report their child's immunizations to TPH.

https://www.toronto.ca/community-people/health-wellnesscare/health-programs-advice/immunization/report-studentvaccination/ https://www.toronto.ca/community-people/health-wellnesscare/health-programs-advice/immunization/toronto-publichealth-appointment-booking-system/ https://www.toronto.ca/community-people/health-wellnesscare/health-programs-advice/immunization/report-studentvaccination/

## **New Toolkit**

Choosing Wisely Canada's new toolkit features easy-to-use tools and resources to help clinicians and caregivers manage bronchiolitis appropriately.





V1 Last Updated: October 2023

### PEDIATRIC VIRAL PRESCRIPTION

Provides other ways to help relieve symptoms to avoid unnecessary antibiotic prescriptions.



D	
<b>Pediatrics</b>	Patient Name:
FOR CHILDREN AGES 3 MONTHS & O	
<b>Pediatrics</b> FOR CHILDREN AGES 3 MONTHS & OLDER	Patient Name: Date:
	d with today suggest a viral infection:
Common cold (upper respiratory	rtract infection): Cough can last 3-4 weeks
Bronchiolitis: Cough can last 3-4	1 weeks
Sore throat (viral pharyngitis)	
Middle ear infection (otitis media)	ı)
Sinus infection (acute sinusitis)	
Other viral respiratory infection:	
viral infections. Using antib effective for potential future l	ntibiotics because they do not work on biotics when not needed makes them less bacterial infections. They can cause side nd, in rare cases, allergic reactions, or
How to help your child fee	el better and manage symptoms: ———
<ul> <li>Ensure they drink plenty of fluids a <i>For infants, smaller feeds more of</i> </li> </ul>	and get rest ften to meet the same total daily amount of feeds
Wash hands often and stay home	to avoid spreading the infection
	e-counter cough and cold medicines. r pharmacist about using the following to give:
Acetaminophen (e.g., Tylenol)	for fever and aches

Ibuprofen (e.g., Advil, Motrin) for fever and aches

### **RECENT SESSIONS**

November 17	COVID-19 Updates and the New Ontario Structured Psychotherapy Program	Dr. Gerald Evans Dr. Paul Kurdyak Dr. Leah Skory
October 27	Respiratory and Flu Season: Counselling Kids & Balancing Workload	Dr. Joan Chan Dr. Janine McCready
October 6	Update on COVID-19, influenza and RSV vaccines	Dr. Zain Chagla Dr. Elizabeth Muggah
September 15	Preparing for the fall	Dr. Kieran Michael Moore Dr. Daniel Warshafsky
December 15	Winter virus season and Changes to breast cancer screening in Ontario	Dr. Allison McGeer Dr. Jonathan Isenberg Dr. Anna M. Chiarelli Maggie Keresteci


**Previous webinars & related resources:** 

https://www.dfcm.utoronto.ca/covid-19-community-practice/past-sessions

# Accessing Previous Sessions and Self Learning

#### **Previous webinars & related resources**

#### https://www.dfcm.utoronto.ca/covid-19-community-practice/past-sessionspast-sessions





Driving Real Change for Family Doctors Today

Join us on January 26 & 27

### Gain insights from over 30 family physician leaders! Topics include:



Standing up for Family Doctors



Tips and Tricks in Your EMR That Will Make You Very Happy



Helping Reduce Administrative Burden Today: New Bots and Al at Your Service



View the agenda and register today <u>www.ocfpsummit.ca</u>

Earn up to 39 Mainpro+ Credits Conference content available on-demand until April 30, 2024

### **Questions?**

Webinar recording and curated Q&A will be posted soon <u>https://www.dfcm.utoronto.ca/covid-19-community-practice/past-sessions</u>

Our next Community of Practice: February 9, 2024

Contact us: <u>ocfpcme@ocfp.on.ca</u>

*Visit*: <u>https://www.ontariofamilyphysicians.ca/tools-resources/covid-19-</u> <u>resources</u>

The COVID-19 Community of Practice for Ontario Family Physicians is a one-credit-per-hour Group Learning program that has been certified for up to a total of 32 credits..

Post session survey will be emailed to you. Mainpro+ credits will be entered for you with the information you provided during registration.



